Antiobesity effect of MK-5046, a novel bombesin receptor subtype-3 agonist.
Guan
Xiao-Ming
XM
Department of Metabolic Disorders, Merck Research Laboratories, Rahway, New Jersey 07065-0900, USA. xiaoming.x.guan@gsk.com
Metzger
Joseph M
JM
Yang
Liming
L
Raustad
Kate A
KA
Wang
Sheng-Ping
SP
Spann
Stephanie K
SK
Kosinski
Jennifer A
JA
Yu
Hong
H
Shearman
Lauren P
LP
Faidley
Terry D
TD
Palyha
Oksana
O
Kan
Yanqing
Y
Kelly
Theresa M
TM
Sebhat
Iyassu
I
Lin
Linus S
LS
Dragovic
Jasminka
J
Lyons
Kathy A
KA
Craw
Stephanie
S
Nargund
Ravi P
RP
Marsh
Donald J
DJ
Strack
Alison M
AM
Reitman
Marc L
ML
D000818:Animals; D019440:Anti-Obesity Agents / Q000494:pharmacology*; D001794:Blood Pressure / Q000187:drug effects; D001835:Body Weight / Q000187:drug effects; D004285:Dogs; D004305:Dose-Response Relationship, Drug; D004435:Eating / Q000187:drug effects; D004734:Energy Metabolism / Q000187:drug effects; D006339:Heart Rate / Q000187:drug effects; D007093:Imidazoles / Q000494:pharmacology*; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D011720:Pyrazoles / Q000494:pharmacology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D018004:Receptors, Bombesin / Q000819:agonists* / Q000032:analysis
C556243:1,1,1-trifluoro-2-(4-(1H-pyrazol-1-yl)phenyl)-3-(4-((1-(trifluoromethyl)cyclopropyl)methyl)-1H-imidazol-2-yl)propan-2-ol; D019440:Anti-Obesity Agents; D007093:Imidazoles; D011720:Pyrazoles; D018004:Receptors, Bombesin; C107120:bombesin receptor subtype 3